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ABSTRACT
The salivary gland produces saliva that aids in digestion and in maintaining homeostasis
in the oral cavity. Saliva production is disrupted in Sjögren’s Syndrome (SS), where the salivary
gland is attacked by the immune system, leading to loss of function and hyposalivation. SS is
thought to be accompanied by changes in the salivary epithelium, which are incompletely
understood. In this study we have used the non-obese diabetic (NOD) mouse as a model for SS
to study the changes in salivary gland epithelium, as these models present autoantibodies and
other characteristics such as immune infiltrates similar to those found in SS patients. To
quantify and explore glandular changes in both mouse and human tissue, epithelial proteins
marking specific cell types were compared using multiplexed immunohistochemistry and
immunofluorescent microscopy. Epithelial markers were characterized in human SS and two
types of human control tissue, autopsy, and non-SS biopsies, and these results were compared
to NOD epithelial tissue and healthy CD-1 age-matched controls. Specific protein markers used
included cytokeratin 7 for ductal cells, cytokeratin 5 for undifferentiated progenitor cells,
aquaporin 5 (AQP5) for acinar cells, smooth muscle α-actin for myoepithelial cells, and a small
panel of innervation specific markers. In order to determine the effect of disease progression
over time on the submandibular salivary epithelium, protein level and localization were
compared between SS-like NOD tissue and CD-1 age-matched control tissues. Changes in
protein levels were quantified using specialized quantitative immunohistochemistry,
incorporating newly developed protocols. In order to evaluate the efficacy of the NOD mouse
model as a model for human disease, mouse tissues were compared to human SS and control

tissues. We conclude that while SS-like disease progression in the NOD mouse model occurs
over time, the phenotype of the gland at time points previously characterized as late-stage
disease may represent an earlier phenotype of diagnosed human SS, which is typically detected
at a late stage.
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INTRODUCTION
Sjӧgren’s Syndrome (SS) is a chronic autoimmune disease that targets the salivary and
lacrimal glands, resulting in a progressive loss of salivary secretion (Gao 2006). Loss in exocrine
function is often undetected until there has been a significant decrease. Clinical presentation of
SS in humans is characterized by the presence of xerostomia (dry mouth) and
keratoconjunctivitis sicca (dry eyes) (Venables 2004). These disease manifestations can be
debilitating to patients, who are forced for the duration of their life to use synthetic over-thecounter eye drops and mouth preparations to simulate tears and saliva. In addition, there are
prescription medications to help combat dry eyes, dry mouth, and the systemic manifestations.
These medications can help to lessen symptoms, but do not directly treat the disease (Sjӧgren’s
Syndrome Foundation April 2014). There is currently no cure for SS.

Diagnosis and Prevalence of Sjögren’s Syndrome
SS is one of the most prevalent autoimmune diseases in the United States (as reviewed
in Fox 2007). The National Arthritis Data Workgroup indicates that the presence of SS has been
estimated at 1.3 million cases out of the approximate population of 214.8 million within the
United States. Out of these cases, the ratio of instances for women to men is 9:1, indicative of a
possible correlation between disease expression and gender (as reviewed in Lavoie 2011),
although other research suggests that the female to male ratio may be closer to 20:1 (Westhoff
2010). Part of the reason for the uncertainty is the difficulty in diagnosing SS and the changing
criteria. The criteria currently proposed by the American College of Rheumatology (ACR) for SS
diagnosis includes the expression of 2 out of 3 manifestations that are necessary to be present

for a diagnosis. These diagnostic criteria include an ocular surface damage test, a blood test
positive for certain SS associated antibodies, and a salivary gland biopsy positive for
lymphocytic infiltrates (Shiboski 2012). Since Sjӧgren’s Syndrome is often expressed along with
other autoimmune diseases such as rheumatoid arthritis, or systemic lupus erythematosus
(Tincani 2013), which is known as secondary Sjӧgren’s Syndrome, it can be difficult to diagnose
and to study.Considering the large number of individuals affected by SS, it is important to find
effective, long-lasting treatments to improve the quality of life for these individuals.

Use of the NOD/ShiLtJ Mouse Model for the Study of Sjögren’s Syndrome
In order to study SS in the laboratory, mouse models are used, including the non-obese
diabetic (NOD/ShiLtJ) model (Jonsson 2006, Lavoie 2011). The NOD/ShiLtJ mouse model is
useful for study of SS due to the presence of the SS phenotype including reduced salivary and
lacrimal production accompanied by lymphocytic infiltrate. Both human SS patients and the
NOD/ShiLtJ mouse model develop disease-characteristic lymphocytic infiltrates increasing in
prevalence and size with disease progression. Lymphocytic infiltrates found in both the salivary
and lacrimal glands have been found to contain T cells and macrophages (Venables 2004, Lavoie
2011). These lymphocytic cells within the infiltrates may target specific proteins within these
glands, and could be a causative factor in the loss of function that results from disease
progression. Lymphocytic infiltration onset in the salivary and lacrimal glands of the NOD/ShiLtJ
model occurs at approximately 12 weeks of age and is present at approximately 16-20 weeks of
age, resulting in a loss of exocrine function by 20 weeks (Lavoie 2011).

As in humans, SS-like symptoms in the NOD/ShiLtJ model are accompanied by the
detectable presence of specific autoantibodies, including autoantibodies to nuclear proteins,
namely anti-Ro/SS-A, and anti-La/SS-B, and are correlated with secretory dysfunction. Other
autoantibodies, including autoantibodies that target innervation receptors, such as muscarinic
receptor 3 and beta adrenergic receptor, enhance the similarity between the NOD/ShiLtJ model
and clinical presentation as they are also present in SS human patients. Anti-muscarinic
receptor 3 may also be a potential influence on secretory dysfunction within both human SS
patients and the animal model, possibly through the blocking of neurotransmission through this
receptor (Venables 2004). Although the presence of autoantibodies and lymphocytic infiltrates
may play a large role in the development of SS in the NOD/ShiLtJ mouse model, other causative
factors thought to play a role in the development of SS in humans may also be factors in
contributing to development of disease such as previous systemic viral infection and epigenetic
changes (Venables 2004). In addition to similar immune system characteristics between human
SS patients and the NOD/ShiLtJ mouse model, the mouse model also exhibits similar gender
differences in presentation, with the females expressing salivary symptoms earlier than males
by a matter of weeks. This correlates to the sexual dimorphism observed in clinical presentation
of SS in humans. Since the NOD/ShiLtJ mouse model is extremely similar to human SS in both
autoantibodies present and clinical presentation, the model should be an excellent vehicle for
studies and research work involving SS (Lavoie 2011).

The Epithelium of the Salivary Gland Changes in Sjögren’s Syndrome
In the salivary gland, epithelial acinar cells organized in a spherical structure secrete
saliva, facilitated by the myoepithelial cells which surround them. The myoepithelial cells
contract, squeezing the acinar cells, which then release the saliva into the hollow lumen located
in the center of the acinar units (Holmberg 2014 and Tucker 2007). This secretion is released
from vesicles in the acinar cells and travels through the lumen, which is continuous with the
ductal network. This allows the saliva to travel through the salivary gland to the oral cavity as
the ductal cells modify it so that it is capable of performing all of the needed functions. During
disease progression in SS, changes within the salivary gland occurring with disease progression
and loss of function have been examined, including a global increase in the ductal epithelium
(Ihrler 2000, Konttinen 2006) which is required for saliva transport from the gland. In humans,
atrophy of aquaporin 5 (Aqp5)-positive secretory acinar epithelium is thought to occur in SS
(Daniels 1984), along with dysregulation of innervation (Konttinen 2006), suggesting a loss in
capability of saliva production and secretory ability.

The Role of Innervation in the Salivary Gland
Autonomic innervation within the salivary gland has been shown to play a large part in
both tissue development and the regenerative capabilities of the gland. Neuronal-epithelial
interactions are important in submandibular gland (SMG) salivary function in animal models
(Ferreira 2013). The two subtypes of autonomic innervation, sympathetic and parasympathetic,
are thought to influence both tissue development and the regenerative capabilities of the
salivary glands differently. It is suggested that both parasympathetic and sympathetic

innervation play roles in the development of the gland, with parasympathetic innervation
influencing glandular development prior to birth and sympathetic innervation influencing
specifically the development and differentiation processes of mature acinar and ductal cells
postnatally (Proctor 2007).
Parasympathetic innervation is important for regeneration and homeostasis of the
salivary gland. During regeneration, the importance of parasympathetic innervation can be
observed in a ductal ligation model where glands that showed no parasympathetic
functionrecovered to only approximately 60% of stimulated secretory functionality compared
to those that were normally innervated (Proctor 2007). Also, in an irradiation model of
regeneration, it was observed that decreased levels of parasympathetic innervation due to
irradiation are correlated with a decreased regenerative capability of salivary glands, whereas
normal or increased levels of parasympathetic innervation promotes tissue regeneration after
irradiation (Knox 2013). Parasympathetic innervation is not only important for function, it is
also important for development. A study from Knox, et al. showed a necessity for
parasympathetic innervation in maintenance of the K5-positive progenitor cells during
development (Knox 2010). In the future, manipulation of the balance of innervation within the
gland in order to influence the K5 positive progenitor pool could provide a potential form of
treatment for clinical patients suffering from hyposalivation as well as other forms of salivary
gland dysfunction. Within the salivary gland tissue of individuals suffering from SS, these
changes in progenitor cells due to aberrant innervation and function could also contribute to
the loss of function that occurs.

Examination of Epithelial and Innervation Changes in the NOD/ShiLtJ Mouse Model of
Sjögren’s Syndrome
In this study, to characterize the phenotypic differences in innervation and epithelial
markers between human SS patients and the NOD/ShiLtJ model, we used quantitative
immunohistochemical staining and imaging. We hypothesized that the NOD/ShiLtJ mouse
model for SS would mimic the phenotypic changes reported in human SS patients during SS
disease progression. In order to examine these phenotypic changes through disease
progression in the NOD/ShiLtJ mouse model as compared to CD-1 control age-matched control
mice, we examined multiple markers in the submandibular salivary gland (SMG) at the 12, 18,
and 22 week time points using a tissue microarray. Based on prior studies, these specific time
points were chosen to be representative of early, mid, and late disease in the female mice. We
developed and employed a new method of image processing and quantitative
immunohistochemistry to assess the degree of change in the NOD/ShiLtJ model as compared to
control. We examined phenotypic structural differences known to occur in human SS patient
salivary tissue, such as an increase in ductal quantity (Konttinen 2006), that can be marked and
quantified using specific markers, such as cytokeratin 7 (K7) (Nelson 2013), in order to validate
our quantification method. In order to examine the epithelium we used markers for K7,
marking ducts, AQP5, marking acinar epithelium, (SMα-A), marking myoepithelium, and sodium
potassium ATPase (Na/K-ATPase), highlighting total salivary epithelial tissue. In order to
examine innervation within the gland, βIII tubulin (βIII) was used to mark total innervation,
while tyrosine hydroxylase (TH) and Gfrα-2 were used to identify sympathetic innervation and
parasympathetic innervation, respectively. Since it is known that increased sympathetic

innervation can result in decreased ability of SMG regeneration (Knox 2013), we chose to
examine the epithelial progenitor marker K5 in order to determine if this population was
reduced in the NOD/ShiLtJ model as compared to control. Both parasympathetic and
sympathetic innervation are thought to influence SMG regeneration independently and
differently, so it is important to examine both types of innervation and compare their levels and
localization in this study. Since innervation is thought to be dysregulated in human SS
(Konttinen 2006), we examined both parasympathetic and sympathetic innervation in order to
determine any differences in ratio or levels expressed between the CD-1 control mouse and
NOD/ShiLtJ mouse model during disease progression.

MATERIALS AND METHODS
Immunohistochemistry Using Formalin-Fixed, Paraffin Embedded Tissues in a Microarray
In order to examine both mouse and human tissues, tissue microarrays (TMAs) were
constructed from paraffin embedded samples. Mouse TMAs were constructed using 104
randomly placed spots per slide consisting of 18 and 22 week CD-1 and NOD/ShiLtJ
submandibular salivary tissues and other staining control tissues including postnatal SMG,
smooth muscle and thymus. Human labial gland biopsies obtained from the University of Oslo,
Norway. Human TMAs were constructed using 39 spots of human samples and included an
additional four mouse CD-1 tissue spots for staining controls. In order to prepare paraffin TMAs
for staining and imaging, they were first deparaffinized, followed by an antigen retrieval step
prior to antibody application, and imaging of the tissue to examine the fluorescence. Prior to
deparaffinization, the 0.5 μm paraffin sections were baked in an incubator at 60°C for 1 hour.
For deparaffinization, they were then placed in a glass coplin jar basket and were placed in a
series of 11 jars for 10 minutes each containing different solutions in the order: Histochoice,
Histochoice, 100% ethanol, 100% ethanol, 95% ethanol, 95% ethanol, 70% ethanol, 70%
ethanol, 1 X phosphate buffered saline (PBS), 1 X 0.1% triton, and 1 X PBS. Antigen retrieval was
completed using a previously described procedure (Nelson 2013). Slides were rinsed four times
in 1 X PBS. Blocking was completed with 10% donkey serum in 3% bovine serum albumin (BSA)
for approximately 1 hour. Primary antibody was applied and slides were incubated at 4°C
overnight. Primary antibodies that were used in this study (table 1) include β-III tubulin, GFRα2,
tyrosine hydroxylase, DAPI, cytokeratin 7 (K7), sodium/potassium ATPase (Na/K-ATPase),
cytokeratin 5 (K5), aquaporin 5 (Aqp5), and smooth muscle α-actin (αSMA). After incubation in

primary antibody, slides were rinsed twice in 1 X PBS. Secondary antibody matching the primary
antibody origin was applied at a dilution of 1:200 and was incubated at room temperature for
one hour. Secondary antibodies used include antibodies for the Cy5 and Cy3 channels, included
those that originated from either mouse, rat, goat, or rabbit and were selected according to
their specificity for the various primary antibodies (Table 1). To prevent non-specific
fluorescence when imaging past the four secondary antibody types, direct conjugate, or
primary antibodies marked directly with a fluorescent tag, were used to prevent the use of
further secondary antibodies. Slides were rinsed twice in 1 X PBS prior to staining with DAPI,
followed by another two 1 X PBS rinses. Slides were then mounted with glycerol media and
imaged on an Olympus IX81 microscope.

Concentration
Target

Manufacturer

Catalog Number

(mg/mL)

Channel Dilution

Tyrosine Hydroxylase

Millipore

AV152

0.08

Cy3

1:100

GFRa2

R&D Systems

AF429

0.20

Cy5

1:100

K5

Covance

LL039

0.49

DC-Cy3

1:100

B3 Tubulin

R&D Systems

LL015

0.33

DC-Cy5

1:100

K7

Abcam

LL019

0.32

DC-Cy 3

1:100

NaKATPase

Epitomics

LL014

0.20

DC-Cy5

1:100

SMA

Sigma

A2547

1-1.50

DC-Cy3

1:500

AQP5

Allimone

LL009

0.16

DC-Cy5

1:100

Donkey anti-goat

Jackson IR

705-175-147

1.5

Cy5

1:200

Jackson IR

711-165-152

1.5

Dy3

1:200

F(ab)2 secondary
antibody
Donkey anti-rabbit
F(ab)2 secondary
antibody
Table 1) Dilutions and channels used for primary and secondary antibody staining used in
immunohistochemical staining. Antibodies used as direct conjugates (DC) created by GE denoted
with in-house catalog numbers for Larsen Lab (LL). Secondary antibodies from Jackson IR used for
GFRa2 and Tyrosine Hydroxylase.

Image Capturing
The images that were used for the quantification process were taken from a 104-spot
tissue microarray (TMA). This microarray was arranged with the two types of mouse model,
NOD and healthy, of various ages in a random arrangement with the intent that the blind
counter (N.P.) would not have earlier knowledge of the origin of each spot with the addition of
postnatal day one control mouse tissue as a staining control. This arrangement also helped to
control for even staining of the tissue during processing of the stains during
immunohistochemistry. In order to compare the differences between the SS-like NOD mouse
model and the CD-1 control mouse model, we quantified immunohistochemical markers within
the submandibular gland and lacrimal glands using antibody staining. As multiplexing was used
for the imaging of this project, multiple markers could be imaged at the same time on the same
section of tissue utilizing different channels that could be selected for with the microscope. For

each spot, up to three images were acquired, which included a DAPI image and could include up
to two images for primary or secondary antibody staining. The antibody stains were assigned to
either the Cy3 or Cy5 channels using the secondary antibodies for Cy3 and Cy5 that stained in
those selected wavelengths.

Quantification Method for Autofluorescent Background Subtraction Using FIJI
For quantifying the immunohistochemical markers observed in various tissue sections,
the computer software program FIJI, ImageJ, version 1.50i, was used to quantify the
immunohistochemistry data for the markers examined in this study. All images, before being
quantified, had to be processed to remove any autofluorescence naturally present in the tissue.
This was done in Fiji using a process that first allowed for the removal of background
autofluorescence based on subtraction of an image of the bleached tissue without antibody
imaged at a matched exposure time. This bleached image was then subtracted from the
fluorescent image. To begin autofluorescence image subtraction, I first opened the two images
in FIJI, and then created a stack using the “images to stack” function. For image registration I
used the function ¨Linear stack alignment with SIFT¨ to ensure the images were properly
aligned. From here, I measured the average pixel intensity in the unstained image using the
measure function and inserted the measurement that resulted into the calculator plus function
under the K1 value, selecting the divide function to divide the stained image by the unstained.
This effectively removed any background autofluorescence found in the stained image by
spatially subtracting the pixels found in the unstained image from the stained image. I then

used the background subtraction function to process the image with a traditional 10 pixel
rolling ball background subtraction in order to eliminate any residual background.

K7 Stained Image

Bleached Image

=-

Final Product Post-Background
Subtraction

=

Fig 1. Subtraction of autofluorescence. Example of new method of autofluorescence image subtraction
using FIJI (ImageJ 2). Note that while there is an inherent background (arrows) in each image, the K7 signal
disappears after bleaching. Scale bar 100µm.

Rolling Ball Background Subtraction Method
All images, before being quantified had to be processed to remove any unnecessary
background “noise”. This was done through the program we used to quantify the images in the
form of a background subtraction tool. I used the background subtraction function to process
the image with a 50 pixel background subtraction. The type of background subtraction that
ImageJ uses is described as a “rolling ball” background subtraction and removes the smooth
continuous background, in this case to a radius of 50 pixels as the ball’s dimension (Process May
2014).

ROI Immunohistochemistry Stain Quantification
I then chose five regions of interest (ROIs) within the epithelium as positively stained by
epithelial cadherin (ECAD) on each spot quantified that I felt best represented the tissue as a
whole. These regions of interest were uniform in the form of a square box with dimensions for
the sides of 225 pixels. When converted to micrometers, this was the equivalent of 83.2 μm
with an area of 6922.24 μm2 per ROI. I then used the measure function to find the total pixels
counted for ROIs. The next step was then averaging of ROI pixels per spot, followed by
averaging the spots by mouse and then averaging these counts based on the conditions that
the mice were subjected to. Results were then graphed with the standard error of the mean.

Overlay Quantification Method
To compare the co-localization of K5 and SMα-A in the epithelium using
immunocytochemistry stained tissue microarray spots, the images of K5- and SMα-A-stained
tissue spots were superimposed on each other so that areas stained by multiple markers could
be quantified. Image overlays were created and processed using ImageJ 2 (FIJI v1.50i). Overlays
were created using the “images to stacks” command, followed by registration using the plugin
“Linear stack alignment with SIFT” using default parameters. Images were then separated from
the stack using “stack to images” function. Background subtraction was performed at a value of
50 pixels followed by manual thresholding using the “threshold” function. Color overlays were
created using red and green as original colors using the “color merge” function followed by the
“invert” function in order to visualize the stains. For quantification, the blind counter first found
the epithelial cadherin stain for the spot corresponding to the overlay and selected five ROIs of

225x225 pixels, taking care to avoid both edges of the tissue and areas that were not
epithelium. These ROIs were then saved and an image of the overlay was opened. The regions
were then selected individually, highlighting an area of the tissue and the plug-in “Color
Inspector 3D” was opened for that region. From the drop down display option, “histogram” was
selected, and the button labeled “LUT” was selected, measuring the overall pixels and
percentage of the color by area of the region in a results window for black, red, green, and
yellow. These colors correlated to unstained, SMα-A-positive, K5-positive, and SMα-A/K5-copositive areas respectively. These measurements for each color were then copied and pasted
into an excel sheet where the values for the five ROIs of each color per image were averaged
with each other, yielding an average value per color per image. These values were then
assigned to the mouse of origin (either NOD/ShiLtj or CD-1 control of either 18 or 22 weeks but
labeled such that the blind counter would not have this knowledge) and values were averaged
per mouse, then values were averaged per group of tissue origin. Graphs were produced in
Microsoft Excel depicting group averages and standard error of the mean. This method
provided average pixel counts of each color representing corresponding proteins separated by
age and tissue type for comparison between groups.

RESULTS
Validation of Quantification Method Through Examination of Ductalization
To quantify the changes in epithelial marker expression between the NOD/ShiLtj SS
disease model and healthy CD-1 control mice, we used comparative quantitative
immunohistochemistry. We first examined the known ductal cell marker K7 (Nelson 2013), In
the quantification of K7-stained images (Fig 2a), we observed a statistically significant increase
in levels of K7 present. The level of K7 was significantly increased in the NOD/ShiLtj disease
mouse model as compared to the CD-1 control mice in both the 18 and 22 week time points
(Fig 2b). Statistical significance was determined using a student’s two-tailed T-test with p-values
values ≤0.05 and ≤0.001, respectively, as can be seen in figure 2b. The increase in K7 levels that
I detected in the NOD/ShiLtj mouse is consistent with the ductalization that has been previously
reported to occur in human SS (Konttinen 2006).

Aquaporin 5 Positive Epithelial Area is Decreased in the NOD/ShiLtJ Model
The correlation of levels of Aqp5 and expression patterns with salivary disease is
controversial in the literature. We then quantified expression levels for images stained with
AQP5 (Fig 2a), the marker for the acinar secretory cells, (Fig 2c) and observed decreasing levels
of AQP5 in the disease models as compared to the CD-1 control models. The decrease in
expression was not steep enough to be statistically significant, but persisted through both the
18 and 22 weeks age mice, suggesting a decreasing trend in reduction of acinar tissue in the SS
disease model compared to the control tissue.

Given that ducts have been reported to increase and acinar cells have been reported to
decrease with Sjogren’s syndrome, we also quantified data comparing total epithelial area
marked for by K7 and AQP5 in 22 week mice (Fig 2d). This provided data on the total epithelial
area that was K7+ and AQP5+ in the NOD/ShiLtJ disease mice as compared to the CD-1 control
mice, and we found them to significantly increase and decrease, respectively in the NOD/ShiLtJ
model as compared to control.

Overall Epithelial Area is Unchanged in the NOD/ShiLtJ Model
To compare epithelial cell sub-populations against the whole epithelium, we wanted to
find a protein that was not changed with disease. Na/K-ATPase is a membrane protein that we
have used as a membrane marker in past studies (Nelson, 2013) that is expressed in many cells
but is enriched in epithelial cells relative to mesenchyme cells in the salivary gland. When we
stained for Na/K-ATPase and quantified images (Fig 2a), marking epithelial tissue as a whole, it
was observed that there was no significant change in Na/K-ATPase in the NOD/ShiLtJ mouse
model as compared to the CD-1 control model, as indicated by the p-values (Fig 2e). However,
the graph demonstrates an increasing trend in expression of Na/K-ATPase in the 22 week
NOD/ShiLtJ mice compared to the age-matched control mice (Fig 2e).

A

NaKATPase Aqp5 K7 DAPI
CD-1

NOD/ShiLtJ
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Average Pixels Per Region of Interest

B

Average K7 Positive Pixels
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22 Healthy

22 NOD

C

Average AQP5 Positive Pixels
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D
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2.00E+04
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1.00E+04

5.00E+03
0.00E+00
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22 NOD K7

22 Healthy AQP5

22 NOD AQP 5

Average Pixels Per Region of Interest

E

Average Na/K-ATPase Positive Pixels
5.00E+07
4.50E+07
4.00E+07
3.50E+07
3.00E+07
2.50E+07
2.00E+07
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Fig 2. Ductalization and reduction of secretory epithelium occurs in the NOD/ShiLtJ mouse model.
a) Increased K7 ductal cell marker expression was seen in NOD/ShiLtJ disease model tissue as
compared to CD-1 control tissue in overlays of immunohistochemically stained images showing
stains for DAPI, Na/K-ATPase, AQP5 and K7. Disease progression is shown using both 18 and 22
week old mice. b) Increased expression of K7 ductal marker in epithelial tissue of SMG in NOD/ShiLtJ
as compared to control in both 18 and 22 week mice. c) There was a decreasing trend in expression
of Aqp5 acinar cell marker in epithelial tissue of SMG in NOD/ShiLtJ as compared to control in both
18 and 22 week mice. d) Increased percentages of K7+ area and decreased percentages of AQP5+
area were found to be significant in 22 week mice NOD/ShiLtJ mice as compared to control mice. e)
Constant levels of expression of Na/K-ATPase, an epithelial tissue marker, were seen in SMG tissue in
NOD/ShiLtJ as compared to control in either 18 or 22 week mice. Student’s two-tailed T-test
*p≤0.05, **p≤0.01, ***p≤0.001, scale bar 100µm.

Smooth Muscle α-Actin is Increased in the NOD/ShiLtJ Model
As reduction in myoepithelial cells may contribute to glandular hypofunction in SS, we
examined SMα-A-positive myoepithelial cells. On quantification of the stain for SMα-A (Fig 3a),
a marker for myoepithelial cells, which surround the acinar cells and facilitate salivary
secretion, interestingly, we noticed an increasing trend in SMa-A in 18 week NOD/ShiLtJ mice as
compared to control that continued that reached significance at 22 weeks, correlating to a pvalue ≤ 0.01 (Fig 3b).
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Fig 3. SMα-A-positive myoepithelial expression increases significantly in the 22 Week NOD/ShiLtJ
model. a) Increased SMα-A expression in NOD/ShiLtJ as compared to control mice in overlays of
immunohistochemically stained images marked for DAPI and SMα-A of tissue from 22 week mice. b)
Levels of expression of SMα-A in epithelial tissue of SMG in NOD/ShiLtJ are significantly increased in
the 22 week NOD/ShiLtJ mouse as compared to CD-1 control. Student’s two-tailed T-test p≤0.01,
scale bar 100µm.

Cytokeratin 5-Positive Progenitor Cells Are Increased in the NOD/ShiLtJ Model
Progenitor cells are required for development and regeneration; however, nothing is
known regarding the progenitor cell populations in the NOD/ShiLtJ mouse. We therefore
performed immunostaining to detect the progenitor marker K5 (Fig 4a), marking the epithelial
progenitor cell population, and similarly to SMa-A, observed an increasing trend in the 18 week
NOD/ShiLtJ mice, as compared to control that continued in the 22 week mice, reaching
statistical significance with a p-value of ≤ 0.05 (Fig 4b).
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Fig 4. K5-positive progenitor levels increase similarly to SMα-A in the NOD/ShiLtJ model a)
Increased K5-positive tissue expression in disease model as compared to control in overlays of
immunohistochemically stained images showing stains for markers DAPI and K5 of tissue from 22
week mice. b) Levels of expression of K5 in epithelial tissue of SMG in NOD/ShiLtJ increase
significantly at 22 weeks. Student’s two-tailed T-test p≤0.05, scale bar 100µm.

Innervation is Increased in the NOD/ShiLtJ Model
In order to examine total innervation, we measured βIII-tubulin, and quantified the
stained images (Fig 5a). We observed a significant increase in BIII-tubulin in the NOD/ShiLtJ
model as compared to CD-1 control in both the 18 and 22 week mice, indicating an increase in
total innervation within the SMG tissue. This increase correlated to p-values ≤0.05 for both the
18 and 22 week mice, as seen in figure 5b. Since βIII-tubulin is expressed by both sympathetic
and parasympathetic innervation, this increase could represent an increase in either or both
nerve cell populations.
To specifically examine sympathetic innervation, which negatively correlates with
regeneration, we performed immunohistochemistry to detect tyrosine hydroxylase (TH) (Fig

5a). We observed a significant increase in TH levels in the NOD/ShiLtJ disease model as
compared to CD-1 control in both the 18 and 22 week mice (Fig 5c). This increase was shown to
be statistically significant with p-values ≤0.05 and ≤0.01 for 18 and 22 week mice, respectively.
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Fig 5. Increase in βIII tubulin-positive innervation coincides with an increase in tyrosine
hydroxylase positive innervation in the NOD/ShiLtJ model. a) Increased expression of βIII tubulin
and tyrosine hydroxylase in disease model mice as compared to control in overlay images
immunohistochemically stained for markers DAPI, tyrosine hydroxylase, and βIII tubulin of tissue
from 22 week mice. b) Statistically significant increase in levels of expression of βIII tubulin in
epithelial tissue of SMG in NOD/ShiLtJ as compared to control in both 18 and 22 week mice,
indicating an increase in overall innervation in glands. c) Tyrosine hydroxylase in epithelial tissue of
SMG. Statistically significant increase in levels of expression of tyrosine hydroxylase in epithelial
tissue of SMG in NOD/ShiLtJ as compared to control in both 18 and 22 week mice, indicating an
increase in sympathetic innervation in glands. Student’s two-tailed T-test *p≤0.05, **p≤0.01, scale
bar 100µm.

To specifically examine parasympathetic innervation, we stained and imaged for
Gfrα-2 (Fig 6a). We could qualitatively observe that there was an increase in the levels of Gfrα-2
in the NOD/ShiLtJ mice as compared to the CD-1 control at 22 weeks, but were unable to
accurately quantify this stain due to the high background present in several of the images after
numerous attempts at staining for this marker.
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Fig 6. Gfrα-2-positive innervation also increases in the NOD/ShiLtJ model. a) Increased co-positive
staining for Gfrα-2 and βIII tubulin in image overlays of tissue immunohistochemically stained for
markers DAPI, Gfrα-2, and βIII tubulin from 22 week mice. Scale bar 100µm.

DISCUSSION
Increased Cytokeratin 7 Indicates Ductalization in the NOD/ShiLtJ Model
Since previous research shows that ducts increase within SS salivary tissue
(Konttinen 2006), we used the quantification of ductal marker K7 as proof of concept for our
method of quantification of epithelial markers. As expected, there was a statistically significant
increase in K7 staining (Fig 2a) within the NOD/ShiLtJ mouse model SMG tissue as compared to
CD-1 age-matched controls at both 18 and 22 weeks (Fig 2b), indicating that our method of
quantification was indeed yielding accurate results. In order to examine tissue ductalization, we
examined K7 positive epithelial area and found a significant increase in NOD/ShiLtJ mice as
compared to control at 22 weeks. This increase in K7-positive epithelium indicates that the
NOD/ShiLtJ tissue undergoes ductalization similarly to that reported in human SS previously
(Konttinen 2006).

Aquaporin 5 Positive Epithelium Decreases as Ductalization Occurs
When we examined acinar cell marker AQP5 (Fig 2a) we observed that AQP5 levels
decreased in the NOD/ShiLtJ mice as compared to the healthy controls. Although this trend was
not statistically significant, it was present in both the 18 and 22 week time points. Since this
finding could indicate a mild reduction in the acinar cell populations, we completed further
analysis of AQP5-positive acinar epithelial area which indicated a significant decrease in AQP5
positive area in 22 week NOD/ShiLtJ mice as compared to controls. Although not specifically
addressed in this study, decreased acinar cell populations as a function of disease presence may

indicate hyposalivation which may have contributed to the need for providing wet chow to the
NOD/ShiLtJ mice.

Increased Smooth Muscle α-Actin Occurring in the NOD/ShiLtJ Model is Not Observed in
Human Sjögren’s Syndrome Tissues
Initially during our examination of myoepithelial marker SMα-A (Fig 3a), we
hypothesized that we would see a decrease in expression due to the loss of regenerative ability
and decreased glandular function as a factor of disease progression. If the gland could not
repair or replace damaged myoepithelial cells, we expected the myoepithelial cell population to
decrease. Instead, we observed increasing SMα-A expression in NOD/ShiLtJ mice as compared
to control, becoming significant at 22 weeks (Fig 3b). Similar changes in SMα-A were not
observed in human SS patients as compared to human controls (data not shown). It is possible
that changes in myoepithelium occur earlier in the development of SS and due to the common
late diagnosis of SS were not observed in human patients in this study.

Epithelial Progenitor Marker Cytokeratin 5 Increases With Disease Progression in the
NOD/ShiLtJ Model
Since K5-positive progenitor cells have been reported to be able to contribute to all
epithelial cell types n the embryonic gland (Knox 2010), we examined the levels of K5 present in
the NOD/ShiLtJ model (Fig 4a). We expected the levels of K5 to decrease in the disease model
as compared to control as a result of decreased function and decreased epithelial area
coinciding with decreased regenerative capabilities of the tissue. Instead, however, we

observed an increase in K5 levels beginning at 18 weeks in the NOD/ShiLtJ model as compared
to control that gained significance by 22 weeks (Fig 4b). Increased K5 levels were also present in
human SS tissues as compared to control tissues (data not shown). It is possible that increased
K5 levels in the NOD/ShiLtJ model reflect an increase in undifferentiated progenitor cells or a
loss of cellular identity during disease progression.
In order to examine total epithelium, we quantified Na/K-ATPase and found no
significant change in expression in the NOD/ShiLtJ disease model as compared to the CD-1
control model (Fig 2e). We did note a small, yet non-significant increase in Na/K-ATPase levels
in the 22 week NOD/ShiLtJ model as compared to control, however, since Na/K-ATPase is
expressed in ducts preferentially, we believe this to correlate with the increased expression of
K7-positive ductal tissue seen in the NOD/ShiLtJ mice (Fig 2b).

Increased Innervation in the NOD/ShiLtJ Model
In order to examine total innervation within the salivary glands, we stained and
quantified neuronal specific βIII tubulin (Fig 5a) and found an overall increase in innervation in
NOD/ShiLtJ mice as compared to controls. βIII tubulin levels in the NOD/ShiLtJ model were
significantly increased in both the 18 and 22 week mice (Fig 5b). In order to further characterize
the increase in innervation, we stained and quantified sympathetic innervation marker tyrosine
hydroxylase since sympathetic innervation has been shown to reduce regeneration in the
salivary gland (Knox 2013). When comparing the results of quantification of βIII tubulin with
those of tyrosine hydroxylase, we found there to be a correlation and that the expression of
tyrosine hydroxylase also increased significantly in the NOD/ShiLtJ mice as compared to the CD-

1 controls in both the 18 and 22 week mice (Fig 5c). As increased sympathetic innervation is
known to decrease regeneration within the adult SMG (Knox 2013), this may indicate a loss of
regenerative ability in the NOD/ShiLtJ model. To further characterize changes in innervation, we
also stained for parasympathetic innervation marker Gfrα-2 (Fig 6a), and we found a qualitative
increase in expression of Gfrα-2 in the NOD/ShiLtJ mice as compared to the control mice at 22
weeks of age. As Gfrα-2 stains for parasympathetic innervation, we examined this marker in the
hopes of being able to observe the ratio of parasympathetic to sympathetic innervation within
both control and disease tissue. Due to stain quality, however, Gfrα-2 was not able to be
examined quantitatively. This increase in Gfrα-2 expression, although we could not quantify to
determine a ratio, may indicate increased parasympathetic innervation within the tissue which
could lead to increased maintenance and expansion of the K5-positive progenitor cell
population in accordance with the previously established relationship between K5-positive
basal progenitors and parasympathetic innervation within the SMG (Knox 2010).

CONCLUSION AND SIGNIFICANCE
Overall, we observed that within the NOD/ShiLtJ SS disease model as compared to the
CD-1 control mice, the expression of K7, SMα-A, and K5 increased, indicating an increase in
ducts, myoepithelial cells, and basal progenitors, respectively. Increased K7 levels corresponded
with increased K7-positive ductal areas of epithelium, while areas positive for the acinar marker
AQP5 decreased. Basal progenitor marker K5 levels increased in the NOD/ShiLtJ model, a
phenomena that was reflected in human SS tissue, which may reflect an expansion of
progenitors or a dedifferentiation event due to disease state. Interestingly, increased SMα-A
levels in the NOD/ShiLtJ model did not correspond with the decreased SMα-A levels in human
SS tissues, likely due to the model reflecting an earlier state of disease progression than in
commonly seen in human biopsy. In the NOD/ShiLtJ model, we also observed an increase in the
overall innervation as marked with βIII tubulin, correlated with an increase in sympathetic
innervation as marked by tyrosine hydroxylase within the SMG epithelium. We believe this
increase in sympathetic innervation could contribute to a loss of function within the gland. The
regenerative capabilities of the gland could be impeded through increased sympathetic
innervation, which may provide a possible pathway to the treatment of the symptoms of SS,
through examining further and finding methods to manipulate the innervation pathways within
the salivary gland, influencing functional tissue development. Qualitative observations also
suggested that there is an increase in parasympathetic innervation in the disease model as
compared to the control model; however, further study would be necessary to elucidate the
full extent of influence that both sympathetic and parasympathetic innervation have on the
development of a functional salivary gland.
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